Paediatric lung imaging: The times they are a-changin’ by Tiddens, H.A.W.M. (Harm) et al.
Paediatric lung imaging: the times they
are a-changin’
Harm A.W.M Tiddens1,2, Wieying Kuo1,2, Marcel van Straten2 and
Pierluigi Ciet1,2
Affiliations: 1Pediatric Pulmonology and Allergology, Erasmus MC – Sophia Children’s Hospital, University
Medical Centre, Rotterdam, The Netherlands. 2Radiology and Nuclear Medicine, Erasmus University Medical
Center – Sophia Children’s Hospital, Rotterdam, The Netherlands.
Correspondence: H.A.W.M Tiddens, Pediatric Pulmonology and Allergology, Erasmus MC – Sophia Children’s
Hospital, University Medical Center, Rotterdam, 3015 CE, The Netherlands. E-mail: h.tiddens@erasmusmc.nl
@ERSpublications
CT and MRI are increasingly replacing lung function tests to diagnose and monitor lung diseases in
young children http://ow.ly/6KSb30hRdEz
Cite this article as: Tiddens HAWM, Kuo W, van Straten M, et al. Paediatric lung imaging: the times they
are a-changin’. Eur Respir Rev 2018; 27: 170097 [https://doi.org/10.1183/16000617.0097-2017].
ABSTRACT Until recently, functional tests were the most important tools for the diagnosis and
monitoring of lung diseases in the paediatric population. Chest imaging has gained considerable
importance for paediatric pulmonology as a diagnostic and monitoring tool to evaluate lung structure over
the past decade. Since January 2016, a large number of papers have been published on innovations in chest
computed tomography (CT) and/or magnetic resonance imaging (MRI) technology, acquisition techniques,
image analysis strategies and their application in different disease areas. Together, these papers underline
the importance and potential of chest imaging and image analysis for today’s paediatric pulmonology
practice. The focus of this review is chest CT and MRI, as these are, and will be, the modalities that will be
increasingly used by most practices. Special attention is given to standardisation of image acquisition,
image analysis and novel applications in chest MRI. The publications discussed underline the need for the
paediatric pulmonology community to implement and integrate state-of-the-art imaging and image
analysis modalities into their structure–function laboratory for the benefit of their patients.
Introduction
Until recently, functional tests were the most important tools for the diagnosis and monitoring of lung
diseases in the paediatric population. Functional tests are an indirect method to detect structural lung
changes and are relatively insensitive for the detection and monitoring of localised structural lung changes.
Chest imaging has gained importance in paediatric pulmonology as a diagnostic and monitoring tool to
evaluate lung structure, thanks to technical innovations in computed tomography (CT) and magnetic
resonance imaging (MRI) technology. When searching PubMed using the keywords “lung”, “child” and
“imaging”, over 300 papers have been published since January 2016. Around 220 of these papers include
chest CT or MRI acquisition techniques, image analysis strategies and their application in different disease
areas. Of these papers 80% were related to chest CT and 20% to chest MRI. Together, these papers
underline the importance and potential of chest imaging and image analysis in today’s paediatric
pulmonology practice. The focus of this review is on chest CT and MRI, as these are the modalities where
considerable progress has been made over the past year. For the role of chest ultrasound, positron
emission tomography (PET)-CT and PET-MRI, we refer to recent comprehensive reviews [1–4]. Together,
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these publications underline the need for the paediatric pulmonology community to re-evaluate the role of
the various modalities for the benefit of their patients. The current gap between the world of imaging and
functional tests needs to be bridged. We will briefly discuss the historical context of recent developments,
followed by key developments in chest CT, MRI and image analysis in the past year.
Of sound and vision
Up to 1945, the stethoscope (invented by R. Laennec) was the most important diagnostic tool for
investigating the lung, but then the chest radiograph was accepted by the medical community as a more
sensitive diagnostic tool to evaluate lung structure. This paradigm shift, nearly 50 years after the discovery
of X-rays by W. Röntgen, is nicely documented by a landmark paper published in 1945 by the Royal
College of Medicine, which summarises the pros and cons of chest radiographs versus the stethoscope [5,
6]. Even though major limitations of chest radiographs were recognised at that time, chest radiography has
been widely used ever since as a diagnostic tool to depict lung structure for the detection of lung disease.
The next major breakthrough came when Cormack and Hounsfield developed CT. The first CT scanner
for clinical use was installed in Cambridge in 1971. The first papers describing the use of chest CT in the
paediatric age group began to appear a few years later, in 1977 [7]. Despite its enormous potential in
depicting lung structure, its adaption as a diagnostic tool for paediatric pulmonology has been slow. An
important argument against the use of CT in the paediatric population related to its relatively high
radiation burden compared to CXR. Fortunately, over recent decades, technical innovations in CT scanner
technology and image reconstruction have resulted in a substantial reduction in the radiation dose [8].
Powerful post-processing techniques, such as iterative image reconstruction, allowed reduction of the
radiation dose to levels which are nowadays in the order of 3–6 months background radiation [9].
Furthermore, the possible risks related to radiation, as well as the perception of these risks, are now clearly
described and put into perspective, allowing risk and benefit to be balanced more adequately, without
pitfalls [10–14]. Furthermore, thanks to the development of very fast CT scanners, it is now possible to
scan even rapidly breathing young children without the need for anaesthesia or sedation. As a result of
these innovations, chest CT can now be used more safely in the paediatric population to diagnose and
monitor a wide range of lung diseases. However, the more widespread use of chest CT requires
standardisation of chest CT protocols and breathing manoeuvres to a similar level as has been
accomplished for lung function tests. The paediatric pulmonology community has to take on this
responsibility, together with the radiology community, to accomplish lung volume standardisation.
Every breath you take
Standardisation of breathing manoeuvres for lung function tests has been well implemented throughout
the world. This contrasts sharply with the lack of standardisation for the acquisition of chest CT images. It
has long been recognised that spirometry guidance to standardise lung volume during chest CT can be
important for the proper diagnosis of bronchiectasis and parenchymal diseases on inspiratory images, as
well as for the recognition of malacia and regions of low attenuation on expiratory scans [15, 16].
Spirometry-guided CT improves the diagnostic yield, in particular that of the expiratory chest CT. It has
even been suggested that for cystic fibrosis (CF), an expiratory scan might suffice for the diagnosis of all
relevant pathological changes [17]. Despite these studies showing the potential benefit of
spirometry-guided image acquisition, it has not been implemented on a wide scale to date. New studies
have been published that improve our understanding of the potential benefit of spirometry-guided chest
imaging. To implement such image acquisition in the clinic, close collaboration between pulmonologists
and radiologists is required. Its feasibility for the clinical routine has been described by SALAMON et al. [18],
who outline a practical method to obtain accurate lung volume measurements for the guidance of chest
CT imaging in paediatric patients. This procedure requires training of the subject before each chest CT or
MRI, an MRI-compatible spirometer, and close collaboration between a lung function technician and the
radiographer. Patients are trained to execute a breath-hold with open glottis at total lung capacity level for
the inspiratory scan and at residual volume for the expiratory scan. A good-to-excellent target volume level
for the inspiratory or expiratory scan was achieved in ∼90% of children. Spirometry-guided chest CT scans
have been evaluated in clinical practice in a tertiary care children’s hospital [19]. In this retrospective case–
control study in children aged ⩾8 years, CT scans obtained before and after implementation of a
spirometry-guided CT protocol were compared. Spirometry-guided CT scans (n=50 cases) were matched
by age, sex and diagnosis (CF versus other) to CT scans obtained with voluntary breath-holds in the
6 years before implementation of the spirometry assistance protocol (controls). CT scans were evaluated by
two paediatric radiologists blinded to the study. The most important difference was in the mean±SD
expiratory image density, which was −629±95 HU among cases and −688±83 HU among controls
(p=0.002). The authors concluded that spirometry-assisted CT scans had a significantly greater difference
in lung density between inspiratory and expiratory scans than those performed with voluntary
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breath-holds, thus probably improving the ability to detect air trapping. No appreciable difference in
image quality was detected for the presence of motion artefacts or atelectasis.
It has been established that it is feasible for the spirometry-assisted method to be used successfully in
patients suffering from Pompe disease to determine the function of the diaphragm [20]. Furthermore,
spirometry-assisted MRI has even been used in a large birth cohort study. In this study, two
spirometry-controlled inspiratory and two expiratory MRI scans were acquired within 5 min with a success
rate of 90% [21]. Hence, implementation of spirometry-guided chest CT and MRI is considered feasible
and adds to the diagnostic quality of images. However, it requires the involvement of a lung function
technician, and there are some logistic hurdles to overcome. The need for standardisation is not dissimilar
from that of lung function measurements, where proper training adds to the reproducibility and
interpretation of the test. This developments needs to be driven by the paediatric pulmonology community,
as lung function technicians play a key role in the implementation and execution of procedures.
Let’s stick together
To date, the implementation of CT protocols has been largely performed by local radiology communities
and has been focused on the balance between diagnostic image quality and radiation dose levels [22].
There is a great need for more standardisation of CT protocols between centres, for a number of reasons.
First, for rare lung diseases such as CF, primary ciliary dyskinesia (PCD), bronchiectasis and interstitial
lung diseases, large global clinical networks and registries have been developed to improve our
understanding and treatment of these diseases. In these rare disease communities there is a desire to add
information obtained from images to registries. This can be accomplished best when imaging protocols are
sufficiently standardised to allow centralised scoring, and manual or automated image analysis. The latter
requires a higher level of standardisation. Secondly, chest CT is increasingly used as an outcome measure
in clinical trials for various chest diseases. Clinical trial networks have been set up for the joint execution
of such clinical trials. So far, standardising image quality across centres in relation to radiation dose,
reconstruction kernels, slice thickness, etc. has not been well addressed. Recognising the need for a higher
level of standardisation of chest CT, the Standardised Chest Imaging Framework for Interventions and
Personalised Medicine in CF (SCIFI CF) was founded to characterise chest CT image quality and radiation
doses among 16 CF centres in the European Union (EU), seven in Australia and three in the USA [22].
The authors aimed to standardise CT protocols in children and adolescents in several CF centres. In doing
so, an image quality (Q-factor) is assessed; this incorporates the influence of both dose and spatial
resolution on image quality. Across the 16 EU centres CT protocols varied greatly. However, when
adjusting for differences in preferred spatial resolution and radiation dose, the performance of all CT
scanners (i.e. the Q-factor) was found to fall within a small range. It was concluded that multicentre
standardisation of chest CT in children and adolescents with CF is achievable for clinical care and
management. The SCIFI effort has contributed to the inclusion of chest CT as a primary or secondary
outcome measure in several ongoing clinical trials in CF (e.g. clinicaltrials.gov NCT02950883 and
NCT01270074). Another important standardisation effort has been the completion of guidelines to
homogenise radiation dose for paediatric imaging throughout Europe [23]. Both efforts on image quality
and radiation dose standardisation were carried out in concordance with the protocol optimisation
principle ALARA (As Low As Reasonably Achievable).
To standardise chest MRI across centres and vendors to the level that it can be used for registries and
multicentre clinical trials is considered a major challenge, and it is still early days. There are a number of
reasons for this. First, there are endless possibilities to vary the settings for the sequences. Secondly, there
are substantial differences in the sequences that can be used routinely between vendors. Chest MRI is
currently mostly used in single-centre studies. Methods to standardise image quality for MRI are in
development and are being applied to allow multicentre studies (clinical trial.gov NCT02270476 and
NCT01245933).
When numbers get serious
Today’s radiology reports of chest images for routine care are still largely expert-based, mostly not
standardised, and do not contain quantitative outcome data. In other clinical specialities like cardiology,
quantitative post-processing methods to acquire objective outcome measures are available and well
implemented. For lung diseases in adults, such as chronic obstructive pulmonary disease (COPD), image
analysis systems have been developed to measure airway dimensions, parenchymal density and emphysema
[24, 25]. Scoring systems have also been used to characterise disease progression in a cohort of PCD
patients [26]. Initially, these systems were developed for research purposes, but increasingly they are
finding their way into routine clinical care.
https://doi.org/10.1183/16000617.0097-2017 3
LUNG IMAGING | H.A.W.M. TIDDENS ET AL.
In children, scoring systems have been extensively used to validate chest CT outcome measures in CF [27].
Using the standardised CF-CT scoring system it was shown that the sweat test is an early predictor of later
structural lung disease [28]. Unfortunately, scoring systems such as the CF-CT system are not very
sensitive for the detection and monitoring of early disease and cannot be automated easily. PRAGMA-CF
(Perth-Rotterdam Annotated Grid Morphometric Analysis for CF) is a quantitative grid method to
quantify morphological changes that occur in early CF disease [29], and is based on a morphometric
approach previously used for quantification of advanced CF lung disease. Comparing lung clearance index
(LCI) values to PRAGMA-CF outcomes in 42 infants, 39 preschool and 38 school-aged children, it was
concluded that for infants LCI is insensitive for the detection of structural lung disease and that in
preschool and school-age children LCI cannot replace chest CT to screen for bronchiectasis [30].
A morphometric approach similar to that of PRAGMA-CF is now also applied to other diseases in children
and adults, such as bronchopulmonary dysplasia (BPD) [31, 32] and interstitial lung diseases [33].
Airway disease is an important component of the above-mentioned diseases. For this reason KUO and
co-workers [34, 35] developed the airway–artery (AA) method to measure all visible airway–artery pairs in
a view perpendicular to the airway axis on a 3D-reconstructed bronchial and arterial tree. The AA method
allows an objective diagnosis of bronchiectasis and airway wall thickening. KUO and co-workers [34, 35]
compared airway and artery dimensions in a small group of preschool [35] and school-aged [34] children
with CF and in controls (figure 1). Depending on the age of the patients and the inspiratory level during
CT acquisition, between 50 and 500 AA pairs could be measured per CT. In school-aged children the
number of visible AA pairs was doubled in patients with CF compared to controls due to inflammation
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FIGURE 1 A method for the objective assessment of airway artery dimensions (the AA method) to diagnose
bronchiectasis. Boxplots show the ratio between the outer edge of the airway (Aout) and the adjacent artery
(A). Aout/A ratios are shown for four consecutive groups: control (n=23); first and second cystic
fibrosis-computed tomography (CF-CT1 (n=12) and CF-CT2 (n=12), respectively); and CT scans in a cross
sectional cohort including patients aged 6–16 years (CF 6–16) (n=11). In total, 11262 AA pairs were measured.
Aout/A ratios are plotted against segmental generation (1 is the first segmental bronchus up to the 12th airway
generation peripheral from the segmental bronchus). Control subjects were age-matched for CF patients.
Median ages are 2 years, 3.9 years and 11 years for CF-CT1, CF-CT2 and CF 6–16, respectively. Boxes show
median (horizontal line), interquartile range (box) and 1.5× interquartile range (whiskers). Outliers are shown
as points. Note that for controls, Aout/A ratios were constant, whereas for each of the three CF groups an
increasing and significant difference could be found in Aout/A ratio between the CF and control group from
generation 2 to generation 5 (all p⩽0.02). Furthermore, the difference between CF and controls was bigger for
the oldest CF patients. Note that for generation 9 and higher, no more airway artery pairs were visible on the
scans for control subjects, while airway artery pairs were still visible on the CT scans of CF patients [34, 35].
Reproduced and modified from [34].
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be dependent on the lung volume at which the CT scan was acquired [35]. These findings once more
support the need for volume standardisation for cooperative children during acquisition. In addition, it
objectively showed that a comparison of the outer airway diameter with the artery is more accurate in
assessing bronchiectasis than the inner airway diameter. Finally, KUO et al. [36] showed a good correlation
between the AA method and the PRAGMA-CF and CF-CT scoring methods. Unfortunately, manual
execution of the AA method is very time consuming. For this reason algorithms are in development that
will allow sensitive analysis of airway dimensions for the diagnosis of airway wall thickening and
bronchiectasis [37]. Adding quantitative information on lung CT scans to the routine radiology report is
close at hand, and will be an important step forward for the diagnosis and monitoring of lung diseases.
How quantitative CT markers can be used as outcomes in clinical CF studies has been described in a
review and in comments as part of a special series in the Journal of Cystic Fibrosis [38–40]. Combining
imaging and functional outcomes in clinical studies will be important to improve our understanding of the
effectiveness of novel therapies, such as the very costly cystic fibrosis transmembrane conductance
regulator (CFTR) correctors and potentiators.
Radio Ga Ga
MRI is sometimes described as making pictures with a radio. Will MRI replace CT at some point as the
leading technique for making images of the lung? The first MRI prototype, a radiation-free alternative to
chest CT, was installed in 1977. Although MRI has revolutionised medicine in many disease areas, its use
for lung diseases has lagged behind. The reasons for this include the low-proton density of lung tissue, the
continuous motion of the lung, and the elevated air content, which results in low signal intensity and fast
signal decay. In 1983 the first study was published that included chest MRIs in children [41]. Major
innovations in chest MRI in paediatrics have taken place over the past decade, especially in relation to the
hardware. Fast acquisition techniques, respiratory gating and new high-resolution techniques continue to
close the image-quality gap between CT and MRI [42].The resolution of conventional 1H- MRI for
morphologic imaging is relatively poor, and is inferior to that of chest CT [43]. However, image resolution
has improved considerably over the past decade thanks to the development of novel ultrashort echo (UTE)
(figure 2) and zero echo time (ZTE) sequences, which allow submillimetre high-resolution images to be
obtained [44, 45]. These UTE/ZTE sequences have been applied in quiet breathing neonates [46].
These sequences have been compared to CT in a group of infants with lung diseases, showing that the
lung signal intensity of UTE correlates highly with lung density measured by CT [46]. This would allow
the introduction of quantitative MRI parameters to define lung pathology, such as trapped air and
emphysema, as is routinely done for asthma and COPD patients. Furthermore, to obtain functional
information on lung perfusion an intravenous contrast agent can be applied [47], although the use of
contrast agents for paediatric patients is still debated after evidence of gadolinium deposition in the body
[48]. Alternative MRI techniques could be applied that allow simultaneous perfusion and ventilation
imaging without using contrast [49]. Another interesting development to improve resolution is the use of
inhaled hyperpolarised gases such as 129Xe or 3He, and other inhaled contrast agents to enhance the
spatial resolution of lung airspaces [50]. The heterogeneity of ventilation can be assessed and
hypoventilated areas can be easily identified. Although these techniques add complexity to the procedure
and will increase the challenge of standardisation, they can be of great value as a research tool to improve
a) b)
FIGURE 2 Chest magnetic resonance images of a 15-year-old boy with asthma. Comparison between 3D
spoiled gradient echo (SPGR) and 3D ultra-short echo time (UTE) at 3 T (Dicovery MR750; GE Healthcare,
Chicago, IL, USA). a) 2×2×2 mm end-expiratory breath-hold axial 3D SGPR (TE=0.748 ms); b) 2×2×2 mm
end-expiratory respiratory-triggered 3D UTE (TE=0.032 ms). Note the higher resolution and signal-to-noise
ratio of UTE with better definition of the airways and air wall (arrow).
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our understanding of various lung diseases and to evaluate the efficacy of novel drugs. This technique has
been applied in small cross-sectional studies in CF [51–55] and in asthma [56]. However, for clinical
management in CF it might be sufficient to identify and quantify low-intensity regions related to
hypoperfusion and/or trapped air using spirometer-controlled expiratory 1H-MRI [18] or other strategies
such as normalised T1 and non-contrast perfusion techniques [57]. This needs to be further investigated
in comparative studies.
Hyperpolarised 3He can also be used to assess alveolar size. This has been applied in BPD [58]. In a small
follow-up study in 16 BPD patients, alveolar size was higher than that of former healthy term-born
patients.
Another important advantage of chest MRI over chest CT is that it allows us to acquire simultaneous
information on lung structure and function without using ionising radiation. This opens up new ways to
study lung mechanics in asthmatic subjects [59].
Another exciting novel application is the potential of MRI to visualise lung inflammation and infection. In
a relatively large single-centre study, conventional MRI sequences were used to assess paediatric
pulmonary infection [60]. MRI had comparable sensitivity and specificity to CT for the diagnosis and
monitoring of lung infection. Interesting methods have been developed that could facilitate diagnosing
allergic bronchopulmonary aspergillosis (ABPA) in CF [61]. Furthermore, MRI could be particularly
important for paediatric patients who cannot be exposed to ionising radiation, or in immunocompromised
children who have repeated infections [62]. For lung inflammation detection and monitoring,
diffusion-weighted MRI has been used in CF patients with pulmonary exacerbation [63]. Many of the MRI
innovations described above were initially developed for CF and are now also applied for research in
asthma [64], immunocompromised children [62], pulmonary infections [65], tuberculosis [66], BPD [46, 58],
congenital diaphragmatic hernia [67, 68], pulmonary sarcoidosis [69], and even in the follow-up of a large
birth cohort study [21]. Chest MRI is increasingly used for clinical management in the follow-up of CF
lung disease [43] or for the assessment of central airway dynamics and dimensions [70]. The major
challenge for MRI to make it into the daily clinic is standardisation of MRI protocols across centres and
vendors. This will require a comparison of protocols using phantoms and selection and validation of
comparable vendor-specific sequences.
Report, numbers? Ch-ch-ch-ch changes
For conventional MRI, quantification of morphological changes is more challenging than in CT as its
resolution is lower than that of CT. Using scoring techniques to evaluate 1H-MRI images of 57 patients it
was shown, as in previous studies, that 1H-MRI underestimates mild CF disease and overestimates severe
CF disease compared to CT [43, 70]. In two small cross-sectional studies in paediatric and adult CF
patients using UTE-MRI, chest MRI scores correlated well with chest CT scores [44, 61]. Scoring was also
used to correlate MRI outcomes to LCI in a cross-sectional study that included 97 stable children with CF
aged 0.2–21 years. Overall, correlations were weak but significant. In addition, 25 children had an MRI
before and after therapy that showed significant improvements in several MRI scores except for airway wall
thickness scores [47]. 1H-MRI has also been used to characterise mucus using differences in its intensity
between T1 and T2 weighted images as a method to identify patients at risk for developing ABPA [61].
These promising but discordant results warrant further longitudinal studies comparing the sensitivity for
tracking structural CF lung disease using these improved MRI sequences with that for chest CT. In addition,
it will be necessary to develop more sensitive semi-automated image analysis techniques to replace the
currently used coarse scoring techniques. Only with a sufficiently standardised multi-vendor, multicentre
and multi-sequence MRI protocol will we be able to promote the use of chest MRI on a larger scale.
For quantification of images using inhaled hyperpolarised noble gases as a contrast agent, ventilation
defects are counted, or the volume of ventilation defects is computed and expressed as a fraction of total
lung volume. Using hyperpolarised 3He-MRI, ALTES et al. [55] showed (in a small pilot study) a reduction
in the fraction of poorly ventilated lung tissue in CF patients while on treatment with the CFTR
potentiator ivacaftor. On stopping treatment after 48 weeks, the volume of poorly ventilated lung tissue
increased again to baseline values, showing a pattern similar to baseline MRI. This study suggests that
ivacaftor can improve the ventilation of even structurally abnormal regions of the lung, but that these
effects disappear after therapy is stopped. In using hyperpolarised noble gases to estimate alveolar size, the
apparent diffusion coefficient is used as the outcome measure. In BPD patients, apparent diffusion
coefficient values were significantly greater than in age-matched healthy controls, suggesting that, in the
former, alveoli are enlarged [58].
Other quantitative functional parameters that can be extracted from MRI are central airway dimensions
for the objective diagnosis of malacia [70–72]. Central airway diameters are measured at end-inspiration,
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during a forced expiration and at end-expiration to compute the change in cross-sectional area.
Advantages of this MRI method include that it does not require general anaesthesia, unlike bronchoscopy,
that the impact of a forced expiration and cough on airway diameter can be evaluated, and that it can be
standardised well.
Another great application of chest MRI is that it can be used for quantitative analysis of the function of
the diaphragm (being the most important respiratory muscle) [20]. Image registration and lung surface
extraction are used to quantify lung kinematics during breathing. This allows us to compute the
independent contributions of the diaphragm and thoracic muscles to the respiratory cycle. This quantitative
method was used in a pilot study in Pompe patients and control subjects, and showed minimal motion of
the diaphragm in the presence of mostly thoracic musculature movement in Pompe patients.
Using diffusion-weighted imaging, inflammation hotspots are visible either because free water movement
is restricted due to the increased cellularity or due to an increase in microperfusion in relation to
inflammation. The hotspots were counted over the course of an intravenous antibiotic treatment in CF
patients treated for a pulmonary exacerbation, then compared to a control group of stable CF patients [63].
A striking finding was that at the end of treatment, hotspots were still visible in some patients. Moreover,
quantitative diffusion-weighted imaging-derived parameters, such as the apparent diffusion coefficient,
showed good sensitivity and specificity to detect respiratory tract exacerbations in CF patients. The ability
of diffusion-weighted imaging-MRI to track inflammatory changes has great potential in assessing the
efficacy of currently used exacerbation treatments and to develop more effective novel therapies.
There are many innovative MRI techniques to obtain detailed information on lung ventilation and
perfusion, and a wealth of outcome measures can be extracted from these techniques. However, the
greatest challenge is to select the most robust outcome measures and to validate these outcome measures.
Importantly, such outcome measures should add novel information that impacts clinical decision making.
Furthermore, the feasibility of implementing these techniques across centres using multiple MRI vendors
needs to be established.
Livin’ in the future
We have come a long way in our diagnostic capabilities since the invention of the stethoscope by Laennec.
Innovations in lung imaging and image analysis will change the face of our diagnostic tool kit as we know
it today. We are likely to continue to use the stethoscope, chest radiographs and lung function in daily
practice, but their role and importance for patient care will once more change substantially in the coming
decade thanks to the capabilities of today’s state-of-the-art chest CT and the rapidly developing and
exciting new capabilities of chest MRI. Novel chest CT, MRI and image analysis techniques will improve
our understanding of the pathophysiology and treatment of lung diseases in the paediatric population.
Although, initially, many of the developments were primarily focused on CF, they are now being applied
to other diseases such as BPD, bronchiectasis, interstitial lung diseases, pneumonia, PCD, sarcoidosis,
tuberculosis and congenital lung abnormalities. Close and structured collaboration between the pulmonology
and radiology communities is needed to facilitate further standardisation efforts and for the development of
reference values and automated image analysis of key outcome measures and for the validation of outcome
measures.
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